Aberdeen Group plc Acquires 77,511 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Aberdeen Group plc increased its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 45.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 248,899 shares of the company’s stock after purchasing an additional 77,511 shares during the period. Aberdeen Group plc’s holdings in Structure Therapeutics were worth $4,308,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Mariner LLC purchased a new position in Structure Therapeutics in the 4th quarter worth approximately $665,000. Invesco Ltd. lifted its holdings in shares of Structure Therapeutics by 4.1% during the 4th quarter. Invesco Ltd. now owns 371,767 shares of the company’s stock worth $10,082,000 after acquiring an additional 14,559 shares during the last quarter. Barclays PLC grew its position in Structure Therapeutics by 42.6% in the fourth quarter. Barclays PLC now owns 115,671 shares of the company’s stock worth $3,138,000 after acquiring an additional 34,533 shares in the last quarter. GAMMA Investing LLC grew its position in Structure Therapeutics by 663.8% in the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock worth $152,000 after acquiring an additional 7,627 shares in the last quarter. Finally, Foresite Capital Management VI LLC bought a new position in Structure Therapeutics in the fourth quarter valued at $11,390,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $18.57 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $13.22 and a 52-week high of $45.37. The company’s 50 day moving average price is $19.34 and its 200-day moving average price is $21.29. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -17.69 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GPCR. Citigroup started coverage on Structure Therapeutics in a research note on Friday, May 2nd. They set a “buy” rating and a $60.00 price target for the company. JMP Securities dropped their target price on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating for the company in a research report on Thursday, August 7th. Guggenheim cut their target price on Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd. Finally, HC Wainwright cut their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Structure Therapeutics currently has an average rating of “Buy” and an average target price of $75.71.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.